Practical Takeaways for Patients, Providers, and PayersByJulia Rotow, MD ,Ibiayi Dagogo-Jack, MDDecember 22nd 2025
Limitations of Current Evidence for BRAF V600E-Mutant Metastatic NSCLC and Cross-Trial ComparisonsByJulia Rotow, MD ,Ibiayi Dagogo-Jack, MDDecember 15th 2025
CNS Disease Considerations and Implications for Treatment Selection for BRAF V600E-Mutant Metastatic NSCLC ByJulia Rotow, MD ,Ibiayi Dagogo-Jack, MDDecember 15th 2025
Practical Monitoring Strategies and Early Treatment Assessments in Patients with BRAF V600E-Mutant Metastatic NSCLC ByJulia Rotow, MD ,Ibiayi Dagogo-Jack, MDDecember 8th 2025